$Lenalidomide for relapsed or refractory multiple myeloma$

Lenalidomide for relapsed or refractory multiple myeloma

We report the activity of lenalidomide (revlimide – R), lenalidomide plus dexamethasone (Rd), lenalidomide plus bortezomib plus dexamethasone (RVd) in 34 patients with relapsed and refractory myeloma. For patients who received lenalidomide the overall response rate was 70.5 %. 38 % patients achieved...

Full description

Saved in:

Bibliographic Details
Main Authors:	S. S. Bessmeltsev1, E. V. Kariagina, L. V. Stelmashenko, G. N. Salogub, E. R. Machulaitene, K. M. Abdulkadyrov, N. A. Kotova, I. I. Kostroma, N. V. Medvedeva, L. I. Krylova, E. Yu. Ilushkina
Format:	Article
Language:	Russian
Published:	ABV-press 2014-07-01
Series:	Онкогематология
Subjects:	multiple myeloma lenalidomide complete response very good partial response overall survival
Online Access:	https://oncohematology.abvpress.ru/ongm/article/view/64
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Bortezomib (Velcade) in combination with dexamethasone eor relapsed or refractory myeloma
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01)

Bortezomib (velcade) plus melphalan and prednisone in elderly untreated patients with multiple myeloma
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01)

Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma
by: Johan Lund, et al.
Published: (2018-06-01)

SARS-CoV-2 immune responses in patients with multiple myeloma and lenalidomide maintenance therapy
by: Ioana Martac, et al.
Published: (2024-12-01)

Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET
by: Alessandro Gozzetti, et al.
Published: (2014-08-01)

Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET
by: Alessandro Gozzetti, et al.
Published: (2012-06-01)

Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET
by: Alessandro Gozzetti, et al.
Published: (2012-01-01)

Efficiency of lenalidomide, bortezomib and prednisone (RVP) in patients with newly diagnosed multiple myeloma
by: K. A. Belousov, et al.
Published: (2019-04-01)

Efficacy of lenalidomide, bortezomib, and prednisolone in patients with relapsed or refractory multiple myeloma
by: T. A. Мitinа, et al.
Published: (2015-12-01)

The multicenter experience with bendamustine in the treatment of relapsed and refractory multiple myeloma
by: S. V. Voloshin, et al.
Published: (2015-10-01)

Modern strategies in therapy of elderly patients with multiple myeloma
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01)

Hematopoietic Stem Cell Collection in Multiple Myeloma Patients: Influence of the Lenalidomide-Based Therapy and Mobilization Regimen Prior to Auto-HSCT
by: II Kostroma, et al.
Published: (2018-04-01)

Ixazomib or Lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of elderly transplant-ineligible newly diagnosed multiple myeloma
by: Yan Wang, et al.
Published: (2025-02-01)

Lenalidomide based triplets in relapsed/refractory multiple myeloma: analysis of the Czech Myeloma Group
by: Jiri Minarik, et al.
Published: (2025-04-01)

Therapeutic Benefits of Lenalidomide in Hematological Malignancies
by: Mohammed Shafi Abdulsalam, et al.
Published: (2019-04-01)

COST-EFFECTIVENESS OF POST-AUTOTRANSPLANT LENALIDOMIDE IN PERSONS WITH MULTIPLE MYELOMA.
by: Monia Marchetti, et al.
Published: (2021-04-01)

COST-EFFECTIVENESS OF POST-AUTOTRANSPLANT LENALIDOMIDE IN PERSONS WITH MULTIPLE MYELOMA.
by: Monia Marchetti, et al.
Published: (2021-04-01)

Practical Aspects of the Use of Carfilzomib in Multiple Myeloma
by: SV Semochkin, et al.
Published: (2018-12-01)

Comprehensive analysis of serum cytokines in patients with multiple myeloma before and after lenalidomide and dexamethasone
by: Takuto Tachita, et al.
Published: (2024-07-01)

Brain abscesses caused by Nocardia paucivorans in a multiple myeloma patient treated with lenalidomide and dexamethasone: a case report and review of literature.
by: Jacopo Monticelli, et al.
Published: (2014-12-01)

Elotuzumab in the treatment of patients with refractory and relapsed multiple myeloma Experience of the Lapino Clinical Hospital Oncohematology Department
by: Yu. E. Ryabukhina, et al.
Published: (2023-12-01)

Three-year progression-free survival of a patient with concomitant mucinous adenocarcinoma of the colon with peritoneal dissemination and multiple myeloma who received lenalidomide: a case report
by: Koki Tamai, et al.
Published: (2024-02-01)

Pomalidomide in relapsed and refractory multiple myeloma: multicenter retrospective study
by: V. G. Potapenko, et al.
Published: (2022-07-01)

PHA RMA COE CONOMI CAL EVALUATION OF MULTIPLE MYELOMA TREATMENT WITH REVLIMID (LENALIDOMIDE ) IN THE RUSSIAN FEDE RATION
by: R. Yagudina, et al.
Published: (2015-03-01)

An improved procedure for synthesis of lenalidomide as an active pharmaceutical ingredient
by: Elaheh Ataollahi, et al.
Published: (2025-09-01)

Incidence, characteristics, and treatments of peripheral neuropathy in multiple myeloma patients receiving bortezomib (velcade)
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01)

Clinical and economic implications of using daratumubab with lenalidomide in the 1st and 2nd lines of therapy for multiple myeloma patients
by: О. I. Ivakhnenko, et al.
Published: (2024-05-01)

Biological basis of immunomodulatory preparations using in treatment of multiple myeloma
by: S. V. Semochkin
Published: (2022-11-01)

Treatment of double-refractory multiple myeloma
by: S. V. Semochkin
Published: (2021-09-01)

PHARMACOECONOMIC EVALUATION OF POMALIDOMIDE (IMNOVID) FOR THE TREATMENT OF RECURRENT AND REFRACTORY MULTIPLE MYELOMA
by: M. Yu. Frolov, et al.
Published: (2017-08-01)

Very good partial remission predicts progression-free survival in patients with multiple myeloma
by: A. S. Luchinin, et al.
Published: (2024-01-01)

Bortezomib neurotoxicity treatment of multiple myeloma: single center experience and literature review
by: N. V. Stepanova, et al.
Published: (2022-11-01)

Dose-modified lenalidomide induces sustained hematological response in patients with intermediate to high risk myelodysplasia
by: Alhossain A. Khalafallah, et al.
Published: (2010-05-01)

Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM)
by: Josip Batinić, et al.
Published: (2024-11-01)

EPIDEMIOLOGY OF MULTIPLE MYELOMA ACCORDING TO THE КIROV REGION POPULATION REGISTERS
by: A. S. Luchinin, et al.
Published: (2017-10-01)

Long-term continuous treatment as a new strategy for relapsed or refractory multiple myeloma
by: S. V. Semochkin
Published: (2020-07-01)

Efficiency of pomalidomide therapy in patients with multiple myeloma refractory to lenalidomide
by: I. G. Rekhtina, et al.
Published: (2019-04-01)

Multiple Myeloma-Associated Kidney Disease Complicated by Sudden Death in a 68-Year-Old Man
by: Victoria L. Ogala-Akogwu, et al.
Published: (2024-07-01)

Optimal daratumumab-based regimen for patients with newly diagnosed and previously untreated multiple myeloma: systematic review and component network meta-analysis
by: Xiaohua Huang, et al.
Published: (2025-05-01)

Lenalidomide and its impact on exanthematous reactions: a case report
by: Cristiana Vieira-Maia, et al.
Published: (2025-04-01)